Rasagiline and Dopamine Interaction
Drug interaction information between Rasagiline and Dopamine.
Rasagiline and Dopamine have a documented minor interaction in FDA labeling.
FDA drug labeling documents a minor-severity interaction between Rasagiline and Dopamine. Major interactions are generally avoided, moderate ones may need monitoring or a dose adjustment, and minor ones are usually low-risk. This page shows the documented mechanism and guidance. Label-documented interactions are not a complete safety review, so always confirm your own medications with a pharmacist or doctor. Educational information, not medical advice.
How They Interact
These two drugs work against each other in the brain, which can stop rasagiline from doing its job.
What To Do
Your doctor may need to check if your treatment is still working or consider changing your medications.
FDA Label Information
7.8 Dopaminergic Antagonists It is possible that dopamine antagonists, such as antipsychotics or metoclopramide, could diminish the effectiveness of rasagiline.
Rasagiline Also Interacts With
- Meperidine moderate
- Dextromethorphan moderate
- Tranylcypromine moderate
- Ciprofloxacin minor
- Norepinephrine minor
Dopamine Also Interacts With
- Carbidopa/Levodopa moderate
- Deutetrabenazine moderate
- Digoxin moderate
- Tetrabenazine moderate
- Tranylcypromine moderate
Frequently Asked Questions
Can I take Rasagiline and Dopamine together?
This is a minor interaction. Your doctor may need to check if your treatment is still working or consider changing your medications.
How serious is the interaction between Rasagiline and Dopamine?
This interaction is classified as "minor" severity by the FDA. Minor interactions are unlikely to cause significant problems but should still be mentioned to your healthcare provider.
Why do Rasagiline and Dopamine interact?
These two drugs work against each other in the brain, which can stop rasagiline from doing its job.
Understanding the Rasagiline and Dopamine Interaction
FDA-approved prescribing information for these two drugs flags their combination as a minor-severity interaction. Rasagiline belongs to the MAO-B Inhibitor class and Dopamine belongs to the Inotropic / Vasopressor class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: These two drugs work against each other in the brain, which can stop rasagiline from doing its job. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.
Context around a specific patient determines real-world impact. Rasagiline has 7 total documented interactions on file in this dataset, and Dopamine has 28. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: Your doctor may need to check if your treatment is still working or consider changing your medications. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.
An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Rasagiline or Dopamine based on a web page, speak with your prescriber or pharmacist before making any change.
Sources: FDA Drug Labels (SPL) via openFDA (2026). This is for informational purposes only and is not medical advice. Always consult your healthcare provider about drug interactions.
Read our methodology - how this data is sourced, computed, and verified.